- Conditions
- Menorrhagia
- Interventions
- Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
- Drug · Device
- Lead sponsor
- Abimbola Famuyide
- Other
- Eligibility
- 30 Years to 55 Years · Female only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 77
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Ortho-Cyclen, AG200-15
- Drug
- Lead sponsor
- Agile Therapeutics
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- HIV, Immune Cells (Mucosal and Systemic), Contraception
- Interventions
- levonorgestrel exposure, DMPA exposure, etonogestrel exposure, IUD insertion, subdermal contraceptive implant insertion
- Drug · Device
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 34 Years · Female only
- Enrollment
- 326 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tisagenlecleucel, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas
- Conditions
- Healthy Participants
- Interventions
- EE/LNG, Baxdrostat
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Oral Hormonal Contraceptive Use, Neural Activity, Mood, Hedonic Function
- Interventions
- Levonorgestrel/ethinyl estradiol, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Contraception
- Interventions
- AG200-15, Levora
- Drug
- Lead sponsor
- Agile Therapeutics
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 407 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more
- Conditions
- Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
- Interventions
- Levonorgestrel intrauterine system, Combined oral contraceptives
- Device · Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Coronary Heart Disease
- Interventions
- Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Bariatric Surgery Candidate, Contraception
- Interventions
- ethinyl estradiol-levonorgestrel
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
- Interventions
- SexHealth II, Contraceptive
- Behavioral · Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 14 Years to 21 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Dyslipidaemia
- Interventions
- AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Contraception, HIV
- Interventions
- Levonorgestrel and Ethinyl Estradiol
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)
- Interventions
- transdermal 17β-E2 with cyclic progestin, oral 17β-E2 with cyclic progestin, transdermal EE+LNG
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 14 Years to 30 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Charlottesville, Virginia
- Conditions
- Healthy Participants
- Interventions
- Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Pelvic Pain Associated With Refractory Endometriosis
- Interventions
- BGS649, Placebo
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 42
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
- Conditions
- Premenstrual Syndrome
- Interventions
- Levonorgestrel/Ethinyl Estradiol
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 40 more
- Conditions
- Contraceptives, Oral
- Interventions
- Lybrel, Doxycycline, Oracea, Placebo, Doxycycline 100bid x5 days at the time of bleeding, Subantimicrobial doxycycline daily, placebo daily
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii • Portland, Oregon
- Conditions
- Contraception
- Interventions
- DR-1011
- Drug
- Lead sponsor
- Duramed Research
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 2,235 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 55
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
- Conditions
- Hematologic Malignancies
- Interventions
- Venetoclax, ethinyl estradiol/levonorgestrel
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Lebanon, New Hampshire • Canton, Ohio
- Conditions
- Healthy Female Participants
- Interventions
- Zibotentan, EE/LNG
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Depression - Major Depressive Disorder, Irritability
- Interventions
- Kurvelo, Placebo COC
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 12 Years to 16 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
- Interventions
- MK-8527, LNG/EE
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- South Miami, Florida